Interdisciplinary consensus RE.GA.IN.: view from the gastroenterologist and endoscopist
https://doi.org/10.31146/1682-8658-ecg-242-10-23-29
Abstract
Chronic gastritis holds one of the leading roles in the structure of pathology of the upper gastrointestinal tract, with which practicing specialists of related specialties - gastroenterologists, therapists, endoscopists - meet on everyday basis. The up-to-date generalizing system of views on this pathology is presented in the RE.GA.IN. consensus (2024). We have highlighted and structured the most practical points of the consensus in the context of classification and characterization of the main forms of chronic gastritis, emphasized approaches to diagnosis and dynamic observation, illustrated the supporting endoscopic criteria of the disease. Moreover, we paid special attention to the description of endoscopic patterns of normal and pathological findings using modern endoscopic technologies as an integral factor of interdisciplinary interaction between clinicians and diagnosticians. In our work we tried to specifically and thoroughly address the problem of autoimmune subtype of the condition as one of the most clinically significant at the current moment, but at the same time often underestimated forms of chronic gastritis.
About the Authors
I. A. Podyapolskaya
Asko-Med-Plus
Russian Federation
Russian Federation
A. N. Beliaev
Asko-Med-Plus ; Regional State Budgetary Healthcare Institution Altai state oncology dispensary
Russian Federation
Russian Federation
References
1. Rugge M., Genta R.M., Malfertheiner P; RE.GA.IN; RE GA IN. RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024 Feb 23;73(3):407-441. doi: 10.1136/gutjnl-2023-331164.
2. Carmack S.W., Lash R.H., Gulizia J.M., Genta R.M. Lymphocytic disorders of the gastrointestinal tract: a review for the practicing pathologist. Adv Anat Pathol. 2009 Sep;16(5):290-306. doi: 10.1097/PAP.0b013e3181b5073a.
3. Gocht A., Schumacher U. Description of the normal gastric mucosa in anatomy education: How many leukocytes are acceptable? Clin Anat. 2023 Apr;36(3):441-446. doi: 10.1002/ca.23976.
4. Dayharsh J., Burgart L.Q., A Column. Cap Today. College of American Pathologists. 2001. Available at: http://www.captodayonline.com/ Archives/q_and_a/qa_0701.html Accessed: 01.05.2025)
5. Yagi K., Aruga Y., Nakamura A. et al. Regular arrangement of collecting venules (rac): a characteristic endoscopic feature of helicobacter pylori- negative normal stomach and its relationship with esophago- gastric adenocarcinoma. J Gastroenterol. 2005;40:443-52.
6. Sugano K., Spechler S.J., El- Omar E.M. et al. Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro- oesophageal junction. Gut 2022;71:1488-514.
7. Glover B., Teare J., Patel N. A systematic review of the role of non-magnified endoscopy for the assessment of H. pylori infection. Endosc.Int. Open. 2020; 8 (2): E105-E114.
8. Yuan C., Lin X. - M., Ou Y. et al. Association between regular arrangement of collecting venules and Helicobacter Pylori status in routine endoscopy. BMC. Gastroenterol. 2021;21:389.
9. Villani L., Trespi E., Fiocca R. et al. Analysis of gastroduodenitis and oesophagitis in relation to dyspeptic/reflux symptoms. Digestion. 1998;59:91-101.
10. Trespi E., Broglia F., Villani L. et al. Distinct profiles of gastritis in dyspepsia subgroups. their different clinical responses to gastritis healing after helicobacter pylori eradication. Scand J Gastroenterol. 1994;29:884-8.
11. Banks M., Graham D., Jansen M. et al. British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545-75.
12. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:42-54.
13. Yan L., Chen Y., Chen F. et al. Effect of helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow- up. Gastroenterology. 2022;163:154-62.
14. Chiang T- H., Chang W- J., Chen SL- S. et al. Mass eradication of helicobacter pylori to reduce gastric cancer incidence and mortality: a long- term cohort study on matsu Islands. Gut. 2021;70:243-50.
15. Hooi JKY., Lai W.Y., Ng W.K. et al. Global prevalence of helicobacter pylori infection: systematic review and meta- analysis. Gastroenterology 2017; 153:420-9.
16. Dixon M.F., Genta R.M., Yardley J.H. et al. Classification and grading of gastritis. The updated Sydney system.International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-81.
17. Rugge M., Correa P., Dixon M.F. et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16:1249-59.
18. Shah S.C., Piazuelo M.B., Kuipers E.J. et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis. Gastroenterology. 2021;161:1325-1332.
19. Malfertheiner P., Megraud F., Rokkas T. et al. Management of helicobacter pylori infection: the maastricht VI/florence consensus report. Gut. 2022. doi: 10.1136/ gutjnl-2022-327745.
20. Bordin D.S., Mozgovoy S.I., Livzan M.A., et al.Interdisciplinary consensus RE.GA.IN.: what’s new? Part 1: definitions, Helicobacter pylori-associated and autoimmune gastritis. Effective Pharmacotherapy. 2024; 20 (2): 54-70. (in russ) soi: 10.33978/2307-3586-2024-20-2-54-70.@@ Бордин Д.С., Мозговой С.И., Ливзан М.А. и др. Междисциплинарный консенсус RE.GA.IN.: что нового? Часть 1: дефиниции, Нelicobacter pylori-ассоциированный и аутоиммунный гастрит. Эффективная фармакотерапия. 2024; 20 (2): 54-70. soi: 10.33978/2307-3586-2024-20-2-54-70
21. Pimentel- Nunes P., Libânio D., Marcos- Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European society of gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota study group (EHMSG), European society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365-88.
22. Kawamura M., Uedo N., Koike T. et al. Kyoto classification risk scoring system and endoscopic grading of gastric intestinal metaplasia for gastric cancer: multicenter observation study in Japan. Dig Endosc. 2022;34:508-16.
23. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-9.
24. Akbari M., Tabrizi R., Kardeh S., Lankarani K.B. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: a systematic review and meta-analysis. PLoS One. 2019; 14 (7): e0219865.
25. Bisschops R., Areia M., Coron E. et al. Performance measures for upper gastrointestinal endoscopy: a European society of gastrointestinal Endoscopy (ESGE) quality improvement initiative. Endoscopy. 2016;48:843-64.
26. Ekkelenkamp V.E., Koch A.D., de Man R.A. et al. Training and competence assessment in GI endoscopy: a systematic review. Gut. 2016;65:607-15.
27. Forbes N., Mohamed R., Raman M. Learning curve for endoscopy training: is it all about numbers. Best Pract Res Clin Gastroenterol. 2016;30:349-56.
28. Marcos P., Brito- Gonçalves G., Libânio D. et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the west Gut. 2020;69:1762-8.
29. Vasapolli R., Neuhaus L., Schirra J. et al. Microscopic alterations of the gastric mucosa in preneoplastic lesions as assessed by new- generation endocytoscopy. Endoscopy 2023;55: E998-1000.
30. Uedo N., Ishihara R., Iishi H. et al. A new method of diagnosing gastric intestinal metaplasia: narrow- band imaging with magnifying endoscopy. Endoscopy. 2006;38:819-24.
31. Yao K., Iwashita A., Tanabe H. et al. White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow- band imaging: a new optical sign for differentiating between adenoma and carcinoma. Gastrointest Endosc. 2008;68:574-80.
32. Pfefferle P.I., Keber C.U., Cohen R.M. et al. The hygiene hypothesis - learning from but not living in the past. Front Immunol. 2021;12:635935.
33. Osmola M., Hemont C., Chapelle N. et al. Atrophic gastritis and autoimmunity: results from a prospective, multicenter study. Diagnostics (Basel). 2023;13:1599.
34. Rustgi S.D., Bijlani P., Shah S.C. Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therap. Adv. Gastroenterol. 2021; 14: 17562848211038771.
35. Miceli E., Vanoli A., Lenti M.V. et al. Natural history of autoimmune atrophic gastritis: a prospective, single centre, long-term experience. Aliment. Pharmacol. Ther. 2019; 50 (11-12): 1172-1180.
36. Lenti M.V., Rugge M., Lahner E. et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6:56.
37. Venerito M., Radünz M., Reschke K. et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther. 2015;41:686-93.
38. Kalkan Ç., Soykan I. Polyautoimmunity in autoimmune gastritis. Eur J Intern Med. 2016;31:79-83.
39. Rodriguez- Castro K.I., Franceschi M., Miraglia C, et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed. 2018;89:100-3.
40. Boutzios G., Koukoulioti E., Goules A.V. et al. Hashimoto thyroiditis, anti- parietal cell antibodies: associations with autoimmune diseases and malignancies. Front Endocrinol (Lausanne). 2022;13:860880.
41. Rugge M., Bricca L., Guzzinati S. et al. Autoimmune gastritis: long- term natural history in naive helicobacter pylori- negative patients. Gut. 2023;72:30-8.
42. Rugge M., Fassan M., Pizzi M. et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012;35:1460-6.
43. Neumann W.L., Coss E., Rugge M. et al. Autoimmune atrophic gastritis- pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10:529-41.
44. Kotera T., Yamanishi M., Kushima R. et al. Early autoimmune gastritis presenting with a normal endoscopic appearance. Clin J Gastroenterol. 2022;15:547-52.
45. Kishikawa H., Nakamura K., Ojiro K. et al. Relevance of pepsinogen, gastrin, and endoscopic atrophy in the diagnosis of autoimmune gastritis. Sci Rep. 2022;12:4202.
46. Goldenring J.R. Pyloric metaplasia, pseudopyloric metaplasia, ulcer- associated cell lineage and spasmolytic polypeptide- expressing metaplasia: reparative lineages in the gastrointestinal mucosa. J Pathol. 2018;245:132-7.
47. Coati I., Fassan M., Farinati F. et al. Autoimmune gastritis: pathologist’s viewpoint. World J Gastroenterol. 2015;21:12179-89.
48. Esposito G., Dilaghi E., Cazzato M. et al. Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low- risk region. Dig Liver Dis. 2021;53:467-73.
49. Chen C., Yang Y., Li P. et al. Incidence of gastric Neoplasms arising from autoimmune Metaplastic atrophic Gastritis: a systematic review and case reports. JCM. 2023;12:1062.
50. Goldenring J. No h. pylori, no adenocarcinoma for patients with autoimmune gastritis. Gut. 2023;72:1-2.
Review
For citations:
Podyapolskaya I.A., Beliaev A.N. Interdisciplinary consensus RE.GA.IN.: view from the gastroenterologist and endoscopist. Experimental and Clinical Gastroenterology. 2025;(10):23-29. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-242-10-23-29
Views:
7
JATS XML
Email this article 
